Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
295M
-
Number of holders
-
125
-
Total 13F shares, excl. options
-
61.5M
-
Shares change
-
+5.56M
-
Total reported value, excl. options
-
$62.8M
-
Value change
-
+$5.84M
-
Put/Call ratio
-
1.3
-
Number of buys
-
65
-
Number of sells
-
-44
-
Price
-
$1.02
Significant Holders of SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) as of Q4 2024
150 filings reported holding SGMO - SANGAMO THERAPEUTICS, INC - Common Stock as of Q4 2024.
SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) has 125 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 61.5M shares
of 295M outstanding shares and own 20.89% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (9.37M shares), WASATCH ADVISORS LP (9.23M shares), BlackRock, Inc. (5.19M shares), STATE STREET CORP (5.02M shares), RENAISSANCE TECHNOLOGIES LLC (3.08M shares), MILLENNIUM MANAGEMENT LLC (2.74M shares), Point72 Asset Management, L.P. (2.27M shares), GEODE CAPITAL MANAGEMENT, LLC (2.21M shares), MORGAN STANLEY (1.88M shares), and Ikarian Capital, LLC (1.86M shares).
This table shows the top 125 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.